| abstract |
HIV having the following core structural formula (I) (AA), solid organ transplant rejection, graft versus host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergy or multiple sclerosis CCR5 antagonists for the treatment of symptom are claimed. Another aspect of the invention is that of the invention in combination with one or more other agents useful in the treatment of solid organ transplant rejection, graft versus host disease, inflammatory bowel disease, rheumatoid arthritis or multiple sclerosis. Use of a CCR5 antagonist of formula I or II. |